千伏级分次内监测(KIM)前列腺癌实时图像引导放疗技术历程:从临床试验到临床实践
本文综述了千伏级分次内监测(KIM)技术从2008年概念提出、模拟与体模实验,到2014年首次临床试验及多中心TROG 15.01临床试验的发展历程。KIM在模拟、体模和临床试验中均达到亚毫米精度,TROG 15.01试验证明其多中心可行性,并显示分次内运动触发门控事件率高及对靶区覆盖的显著剂量学影响。KIM正通过商业化及一项300例、10中心临床试验推广。
要点
- KIM在模拟、体模和临床试验中均达到亚毫米精度。
- TROG 15.01试验证明KIM多中心可行,分次内运动触发门控事件率高。
- KIM部署对靶区覆盖有显著剂量学影响。
核心结论
- KIM已从概念发展为临床试验,使前列腺癌SBRT在存在分次内运动时能够安全实施。
研究设计与样本
- 技术发展综述:KIM概念于2008年提出,经模拟和体模实验,2014年启动首次临床试验,并纳入多中心TROG 15.01临床试验。
主要发现
- KIM在模拟、体模实验和临床试验中均观察到亚毫米精度。
- TROG 15.01试验证明KIM多中心可行,分次内运动触发门控事件率高,且KIM部署对靶区覆盖有显著剂量学影响。
临床怎么用
- KIM可在标准直线加速器上无需额外硬件实现分次内运动管理。
- KIM正通过商业化和一项300例、10中心临床试验推广至临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic Body Radiation Therapy (SBRT) schedules for prostate cancer are emerging as a standard treatment approach. However, although high efficacy is achieved in clinical trials, additional efforts at accurate treatment delivery are necessary to maximize the therapeutic ratio in the community setting. Kilovoltage Intrafraction Monitoring (KIM) is a technology developed to address the unmet clinical need of accurate intrafraction motion management without a requirement for additional hardware on standard linear accelerators. This paper describes the journey from bench to bedside of KIM. METHODS AND MATERIALS: The concept of KIM emerged in 2008 in a series of simulations, progressing to phantom experiments commencing in 2010, culminating in the first clinical trial starting in 2014. A series of technical innovations integrating rotational prostate movements, quality assurance, and dynamic multileaf collimator tracking were included within the multi-institutional Trans-Tasman Radiation Oncology Group 15.01 Stereotactic Prostate Adaptive Radiation therapy using KIM clinical trial for prostate SBRT. RESULTS: Submillimeter accuracy of KIM was observed in simulations, phantom experiments, and clinical trials. The Stereotactic Prostate Adaptive Radiation therapy using KIM trial demonstrated multicenter feasibility of use, a high rate of intrafraction motion triggering a gating event, and a significant dosimetric impact of KIM deployment for target volume coverage. KIM is being made available through commercialization with an industry partner, and through a 300-patient, 10-center clinical trial. CONCLUSIONS: The collaboration between researchers, clinicians, and industry has led to KIM being developed from a concept to clinical trials, enabling the safe delivery of prostate cancer SBRT in the presence of intrafraction motion. This journey provides a template for similar bench-to-bedside translational research.
引用
- Keall PJ, Booth J, Eade T, et al. The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic. Int J Radiat Oncol Biol Phys. 2026. PMID: 41558555. doi:10.1016/j.ijrobp.2026.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。